CAJ | 학술논문

我国乳腺癌的发病率在女性恶性肿瘤里发病率居于第1位。分子靶向治疗药物成为近年来肿瘤治疗中的一大热点，表皮生长因子受体酪氨酸激酶抑制剂吉非替尼是 EGFR 敏感突变型非小细胞肺癌的标准一线治疗。近几年国外有临床研究显示吉非替尼对乳腺癌有一定治疗效果，但目前国内此类相关临床研究较少。现将我科诊治的一例吉非替尼治疗转移性乳腺癌的病例报告如下并做文献复习。
아국유선암적발병솔재녀성악성종류리발병솔거우제1위。분자파향치료약물성위근년래종류치료중적일대열점，표피생장인자수체락안산격매억제제길비체니시 EGFR 민감돌변형비소세포폐암적표준일선치료。근궤년국외유림상연구현시길비체니대유선암유일정치료효과，단목전국내차류상관림상연구교소。현장아과진치적일례길비체니치료전이성유선암적병례보고여하병주문헌복습。
Breast cancer is the most common cancer in women ,which continues to be a major cause of morbidity among women in China..Molecular-targeted therapyhas become a critical focus of cancertherapy..Gefitinib is a specific inhibitor of epidermal growth factor receptor-associated tyrosinekinase , which has been commonly used in the standard first-line treatment for NSCLC patients with EGFR mutations..Recently,several foreign clinical studies show that gefitinib is active in patients with breast cancer, but present domestic related clinical researches are extremely rare. We describe the case of a patient that was diagnosed with metastatic breast cancer treated with gefitinib therapy.